Muciclar (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Muciclar, is a mucolytic presented as an inhalation formulation for respiratory tract use. It helps reduce the thickness of mucus and facilitates clearance in patients with cough, bronchitis, COPD or asthma characterized by mucus hypersecretion.

GNH USA supplies Muciclar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established distribution networks and regulatory expertise across European and global markets, and ensures product quality through rigorous quality‑assurance protocols and responsive customer support for procurement and logistics.

Ambroxol Hydrochloride is indicated for respiratory conditions where thick mucus impairs airway clearance. - Cough associated with thick mucus: reduces mucus viscosity to ease expectoration. - Bronchitis: facilitates mucus clearance, helping relieve productive cough. - Chronic obstructive pulmonary disease (COPD): improves airway patency by thinning secretions. - Asthma with mucus hypersecretion: aids in reducing mucus load and supporting bronchodilator therapy.

While most patients tolerate Ambroxol Hydrochloride well, some may experience adverse reactions that vary in frequency and intensity.

Common Side Effects: - Taste disturbance or mild oral irritation - Nausea or mild gastrointestinal discomfort - Transient headache - Cough irritation after inhalation - Dry mouth - Dizziness

Serious or Rare Side Effects: - Allergic skin reactions such as rash or urticaria - Severe bronchospasm or respiratory distress - Anaphylactic shock (rare but potentially life‑threatening)

When prescribing Ambroxol Hydrochloride, clinicians should consider several precautionary measures to ensure safe use. - Assess renal and hepatic function: adjust use in patients with severe impairment. - Monitor for hypersensitivity: discontinue if rash or swelling develops. - Use caution in patients with active bronchospasm: inhalation may provoke irritation. - Avoid concurrent use of other mucolytics without medical guidance. - Store below 25°C: keep in the original container, protect from moisture.

Ambroxol Hydrochloride can interact with other medicines, and awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Anticholinergic bronchodilators (e.g., ipratropium): may counteract mucolytic effect. - Strong CYP450 inhibitors (e.g., ketoconazole): may increase systemic exposure.

Moderate Interactions (Monitor Closely): - Other mucolytics (e.g., N‑acetylcysteine): additive effect on mucus thinning. - Beta‑agonists: monitor for increased cough reflex. - Corticosteroids: no major interaction but observe for combined respiratory effects.